IL6 and breast cancer: Our previous work demonstrated that tumor exosomal miR-9 (targeting SOCS3) and miR-181a (targeting PIAS3) synergistically activate the JAK/STAT signaling pathway, driving MDSC expansion and suggesting novel intervention strategies for IL-6-driven breast cancer [44].